Calcort (deflazacort) vs Agamree (vamorolone)
Calcort (deflazacort) vs Agamree (vamorolone)
Calcort (deflazacort) and Agamree (vamorolone) are both medications used to treat inflammation and certain autoimmune conditions, but they differ in their chemical structure and side effect profiles. Deflazacort is a glucocorticoid, similar to prednisone, and is known to have immunosuppressive and anti-inflammatory effects, but it may also cause side effects typical of steroids such as weight gain, bone loss, and increased susceptibility to infection. Vamorolone is a first-in-class steroidal anti-inflammatory drug that aims to retain the beneficial anti-inflammatory effects of traditional corticosteroids while reducing some of the adverse effects, particularly those affecting growth and bone health, making it a potentially suitable option for individuals, particularly children, concerned about long-term steroid side effects.
Difference between Calcort and Agamree
| Metric | Calcort (deflazacort) | Agamree (vamorolone) |
|---|---|---|
| Generic name | Deflazacort | Vamorolone |
| Indications | Duchenne muscular dystrophy, certain autoimmune diseases | Duchenne muscular dystrophy (investigational) |
| Mechanism of action | Glucocorticoid receptor agonist | Dissociative steroidal anti-inflammatory |
| Brand names | Calcort, Emflaza | Agamree (proposed) |
| Administrative route | Oral | Oral (investigational) |
| Side effects | Cushingoid appearance, weight gain, increased appetite, upper respiratory tract infection, cough, frequent urination | Not fully established; potential for reduced side effects compared to traditional corticosteroids |
| Contraindications | Systemic fungal infections, known hypersensitivity to deflazacort or any of the excipients | Not fully established; similar contraindications to corticosteroids may apply |
| Drug class | Corticosteroid | Dissociative steroidal anti-inflammatory (not yet classified) |
| Manufacturer | Mondobiotech, PTC Therapeutics | ReveraGen BioPharma |
Efficacy
Calcort (Deflazacort) in Duchenne Muscular Dystrophy
Deflazacort, marketed under the brand name Calcort, is a corticosteroid medication that has been studied for its efficacy in treating Duchenne Muscular Dystrophy (DMD). DMD is a genetic disorder characterized by progressive muscle degeneration and weakness. Clinical trials have demonstrated that deflazacort can slow the rate of muscle deterioration in patients with DMD, leading to a delay in the loss of ambulation and a reduction in the development of scoliosis. The drug's anti-inflammatory and immunosuppressive properties are believed to contribute to its therapeutic effects in managing the symptoms of DMD.
The efficacy of deflazacort in DMD was highlighted in a study published in "Neurology" in 2016, which showed that deflazacort-treated patients experienced a slower decline in muscle strength and function compared to placebo. Furthermore, deflazacort has been found to improve pulmonary function and delay the onset of cardiomyopathy, which are common complications associated with DMD. The drug has been approved by regulatory agencies in various countries for the treatment of DMD, providing a valuable option for managing this debilitating condition.
Agamree (Vamorolone) in Duchenne Muscular Dystrophy
Vamorolone, known under the brand name Agamree, is a novel medication that has been investigated for its potential in treating Duchenne Muscular Dystrophy. Unlike traditional corticosteroids, vamorolone is designed to retain anti-inflammatory efficacy while minimizing side effects commonly associated with steroid use. This dissociative steroid has been studied in clinical trials to assess its ability to improve muscle strength and delay disease progression in DMD patients.
Initial findings from clinical studies have been promising, suggesting that vamorolone may offer a favorable balance between efficacy and safety. In a phase IIb trial, patients treated with vamorolone showed improvements in timed function tests, which are critical measures of motor abilities in DMD. Moreover, vamorolone has been associated with fewer side effects typically seen with traditional corticosteroids, such as weight gain and bone fragility. While further research is needed to fully establish the drug's profile, vamorolone represents a potential new avenue for DMD therapy, aiming to improve the quality of life for patients affected by this condition.
Regulatory Agency Approvals
Calcort
-
Food and Drug Administration (FDA), USA
-
Medicines & Healthcare products Regulatory Agency (MHRA), United Kingdom
-
The Federal Institute for Drugs and Medical Devices (BfArM), Germany
Agamree
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Calcort or Agamree today
If Calcort or Agamree are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us